New drug approval for heart health

What happens when your heart threatens to give up on you if you decide not make certain amendments to your fatty diet, which you have been enjoying since years? The cardiovascular system perhaps, requires an intricate detail of love and affection for itself to grant you the health you have been wishing for. Extra cholesterol that comes through your diet, tends to get accumulated in the blood vessels, resulting in the formation of clots, which eventually leads to thrombosis. If these clots get dispatched, the condition may then be termed as embolism, which is worse than the actual stagnant condition.

These clots may result in strokes if they travel to the brain, causing your life sentence to be reduced by a few more words. If a patient has a history of a heart attack or acute coronary syndrome, he should be, and perhaps is advised to take drugs which would help to thin his blood. For such purposes, the US Food and Drug Administration has agreed to the marketing and sale of the drug, Brillinta (Ticagrelor), particularly in a higher dosage, so as to attract less competition. However, this sale technique has served its importance – Astrazeneca had advised its patients to acquire the drug safely on a regimen lasting for a year; with an increment in the sales from a meager 38% to around $144 million within the first six months of its sales.

AstraZeneca’s Brillinta can be used in patients who have had a history of a heart attack, stroke or infarctions which could lead to the former two. The drug basically thins blood, giving the distraught cardiovascular system some hope. Physicians have now been recently talking about the studies that had been conducted between a low-dose aspirin with another which associates the same dose with the aforementioned recently marketed drug. The results have been worthy of its approval and henceforth; general practitioners have been reported with desires to see the study in black and white.  Apparently, as of Pfizer’s uptake of the company ever since last year, the drug is hoped to make a huge success in the market and is expected to make $3.5 billion sales worth per year.